Back to results
US 12,311,018 B2Granted
Targeted neoepitope vectors and methods therefor
AssigneeNantCell, Inc.
InventorKayvan Niazi
Life of this patent
Estimating the term…
Abstract
Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
Claims10
A method of stimulating an immune response in a patient, the method comprising:
- a) generating a recombinant nucleic acid having a sequence that encodes a polytope, wherein the polytope comprises a plurality of filtered neoepitope sequences, wherein the neoepitope sequences are filtered in silico by comparing tumor versus matched normal control of the same patient;
- wherein the neoepitope sequences are filtered in silico to have binding affinity to MHC-II of equal or less than 200 nM;
- wherein the recombinant nucleic acid further comprises a trafficking element that directs the polytope to a sub-cellular location selected from the group consisting of a recycling endosome, a sorting endosome, and a lysosome;
- b) cloning the recombinant nucleic acid into an adenoviral vector;
- c) formulating the recombinant adenovirus into an immune therapy composition;
- and
- d) administering the immune therapy composition to the patient by intravenous injection.
4 more elements
Dependencies are inferred from the claim text.